Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33869619/
1 Department of Hematology, Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang 050000, Hebei Province, China. 2 Central Laboratory, Hebei Senlang Biotechnology Co., Shijiazhuang 050000, Hebei Province, China. 3 Department of Hematology, Second Hospital of Hebei Medical University, Hebei Key Laboratory of Hematology, Shijiazhuang 050000, Hebei Province, China.
-
Mark FeslerApril 25, 2021Thus far there are no proven consolidative or maintenance treatments post CaR T cell therapy, but with continued study one would hope for an emergence of therapies that enhance both the efficacy and safety ...